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DICLOFENAC SUBMICRON PARTICLE CAPSULES DEMONSTRATE
EARLY AND SUSTAINED ACUTE PAIN RELIEF IN A PHASE 3 STUDY
IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY
C. Argoff y, S. Silberstein z, A. Gibofsky x, S. Daniels k, S. Jensen {, C.
Young {. yAlbany Med. Coll., Albany, NY, USA; z Thomas Jefferson Univ.,
Philadelphia, PA, USA; xHosp. for Special Surgery, New York, NY, USA;
k Premier Res. Group, Ltd, Austin, TX, USA; { Iroko Pharmaceuticals, LLC,
Philadelphia, PA, USA
Purpose: Early management of acute pain may impact the severity and
duration of pain. NSAIDs are utilized to treat acute pain but have the
potential for serious dose-related gastrointestinal, cardiovascular, and
renal adverse events (AEs). Investigational submicron particle NSAIDs
using proprietary SoluMatrix technology are being evaluated to assess
the potential to provide effective pain relief at lower doses than
currently available oral NSAIDs. In a Phase 1 study, diclofenac submi-
cron particle capsules 35 mg achieved an early time to maximum
concentration, a similar maximum concentration, and lower systemic
drug exposure compared with diclofenac potassium immediate-release
tablets. In a Phase 2 study, diclofenac submicron particle capsules (18
and 35 mg) provided effective analgesia and were generally well-
tolerated in a validated post-surgical model of mild to moderate pain.
We evaluated the analgesic efﬁcacy of diclofenac submicron particle
capsules in a post-surgical model of moderate to severe pain.
Methods: This Phase 3 multi-center, double-blind study enrolled 428
patients 18-65 years of age who underwent a primary, unilateral ﬁrst
metatarsal bunionectomy with osteotomy and ﬁxation under regional
anesthesia. Patients experiencing a pain intensity rating of 40mm on
a 100mm visual analog scale (VAS) were randomized to receive diclo-
fenac submicron particle capsules (18 or 35mg; TID), celecoxib (400mg
loading dose, then 200mg BID), or placebo. The primary endpoint was
the summed pain intensity difference measured by VAS over 48 hrs
(VAS SPID-48). Secondary endpoints included the VAS pain intensity
difference (VAS PID) at various time points versus placebo.
Results: As presented recently for the primary endpoint (mean VAS
SPID-48), diclofenac submicron particle 35mg (524; P<0.001) and 18mg
(393; P¼0.01) and celecoxib (391; P¼0.011) demonstrated signiﬁcant
pain control compared with placebo. Some pain relief (mean VAS PID)
was apparent in the diclofenac submicron particle 35mg (4.52) group at
30min in contrast to the placebo (0.12) group. Pain control increased
over time for all active treatment groups. At 4h after dose administra-
tion, diclofenac submicron particle 35mg provided better pain control
(VAS PID) versus placebo (P¼0.025; Figure). At 5h after study entry,
signiﬁcant pain control was noted in the diclofenac submicron particle
35mg (9.43; P¼0.002), 18mg (8.35; P¼0.009), and celecoxib (6.62;
P¼0.032) treatment groups versus placebo (2.30; Figure).Overall, the
most frequent treatment-emergent adverse events were localized post-
procedural edema (32.7%, 140/428), nausea (29.7%, 127/428), headache
(12.9%, 55/428), and dizziness (11.7%, 50/428).
ĂConclusions: Lower-dose, submicron particle diclofenac demon-
strated better pain control at 48h (VAS SPID-48) with evidence of
analgesia as early as 30 min after administration compared with
placebo, and was generally well tolerated. These results suggest that
diclofenac submicron particle capsules are a potentially promising
therapeutic option for acute pain.569
MANAGEMENT OF PATIENTS WITH KNEE OSTEOARTHRITIS BEFORE
AND AFTER THE PHILIPPINE CLINICAL PRACTICE GUIDELINE FOR
KNEE OSTEOARTHRITIS
G.Z. Racaza, E.G. Penserga. Philippine Gen. Hosp., Taft Avenue, Manila,
Philippines
Purpose: We aim to review changes in physicians’ practice on the
management of osteoarthritis (OA) before and after the publication of
the Philippine Rheumatology Association (PRA) Clinical Practice
Guidelines (CPG) for knee OA in year 2010. Major highlights of the CPG
were advocacy of paracetamol as ﬁrst-line pharmacologic therapy fol-
lowed by tramadol, good evidence for usage of glucosamine sulfate,
limitation of NSAIDs usage, and emphasis on rehabilitation and lifestyle
modiﬁcation/advice.
Methods: This study reviewed clinical charts of patients diagnosed
with primary OA (American College of Rheumatology criteria) in the
Philippine General Hospital Arthritis Clinic from January to December
2009 and January to December 2011. Data regarding conventional
management (non-pharmacologic and pharmacologic) and comple-
mentary/alternative therapies on the ﬁrst visit were extracted.
Continuous data were described using means and standard deviations
while nominal data were described using frequencies and percentages.
T-test for two proportions were used to compare use of different
pharmacologic and alternative treatment pre- and post- CPG. P-value
less than 0.05 were considered signiﬁcant.
Results: One hundred eleven patients were included in the study (60
from 2009 and 51 from 2011). Mean age of symptom presentation and
diagnosis were 59.7 years (SD: 10.3 years) 63.2 years (SD: 9.9 years),
respectively. Majority (81.08%) were females. Mean BMI was 26.5 kg/m2
(SD: 5.03), considered obese stage I. The most common presentation
was knee pain (69.8%), majority (76.48%) of which were bilateral. There
were no signiﬁcant differences (p-value 0.723) between the mean age
between pre- (mean 59.3 years; SD 1.5 years) and post-CPG patients
(mean 60.1 years; SD 1.3 years). Likewise, there were no signiﬁcant
differences in sex (p-value 0.2529) and proportion of dyspeptics (p-
value 0.4760). Mean BMI is higher among pre-CPG patients (mean 27.9;
SD 0.78) compared to post-CPG (mean 25.69; SD 0.56) and the result is
statistically signiﬁcant (p-value 0.03). There were statistically more
patients post-CPG who had Kellgren Lawrence score of 2 compared to
pre-CPG patients. The two populations had no signiﬁcant difference
across the rest of the scores. The use of paracetamol is signiﬁcantly
higher among post-CPG patients (54/60, 90% vs pre-CPG 33/51, 64.71%;
p-value 0.0013) but the use of tramadol before and after CPG publica-
tion is not statistically signiﬁcant (p-value 0.1119). Use of NSAID (COX-1
inhibitor) and COX-2 inhibitors was signiﬁcantly lower after the CPG
publication [(5/60, 8.33% vs pre-CPG 17/51, 33.33%; p-value 0.013) and
(6/60, 10.17% vs pre-CPG 25/51, 49.02%; p-value 0.000), respectively].
Glucosamine sulfate use was slightly higher post-CPG (31/51, 51.67%)
compared to pre-CPG (25/60, 49.02%) but this difference was not
statistically signiﬁcant (p-value 0.7810). Use of non-pharmacologic
interventions was signiﬁcantly higher post-CPG (49/60, 81.67%
compared to pre-CPG 12/51, 23.53%, p value 0.0000).
Conclusion: The published CPG by the PRA signiﬁcantly changed the
physicians’ management of patients with OA. Whether it has impacted
the patients’ symptoms, quality of life and overall satisfaction, however,
remains to be determined and can be the subject of studies in the near
future.570
A SINGLE INTRA-ARTICULAR INJECTION WITH IL-4 PLUS IL-10
AMELIORATES BLOOD-INDUCED CARTILAGE DEGENERATION IN
HAEMOPHILIC MICE
L. van Vulpen, M.E. van Meegeren, G. Roosendaal, K. Coeleveld, L.
Nieuwenhuizen, S.C. Mastbergen, F.P. Lafeber. UMC Utrecht, Utrecht,
The Netherlands
Purpose: Exposure of joint cartilage to blood can occur after joint
trauma, during or after major joint surgery, or due to hemophilia. This
ultimately leads to joint damage, both by direct effects of blood on
cartilage and via synovial inﬂammation (Lafeber et al., Haemophilia
2008). The cytokines interleukine (IL)-4 and IL-10 are known as
modulatory cytokines. A combination of IL-4 plus IL-10 protects against
blood-induced cartilage damage in vitro (van Meegeren et al., Osteoar-
thritis & Cartilage 2012). It has been hypothesized that the combination
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this study it is investigated whether a single intra-articular injection of
IL-4 plus IL-10 immediately after a joint bleed limits cartilage damage in
an in vivo haemophilia mouse model.
Methods: Factor VIII knockout mice were punctured once with a needle
below the patella to induce a joint bleed. Subsequently IL-4 plus IL-10
(n¼24) or vehicle (n¼24) was injected intra-articularly once. After 35
days, the knee joints were examined for cartilage damage by macro-
scopic and microscopic evaluation using the OARSI histopathology
score speciﬁc for mice for cartilage degeneration and the Valentino
score for synovial inﬂammation. The left knee joint in both groups
served as an unaffected control.
Results: Induction of a joint bleed led to a signiﬁcant increase in
macroscopic remains of a joint bleed and to an increase in joint
diameter in both groups compared to the unaffected joints (all p<0.05
compared to control). Although not statistically signiﬁcant, the IL-4
plus IL-10 injected joints tended to present less remains of a joint
bleed compared to the vehicle injected joints (46% versus 58%;
p¼0.386). Moreover, the diameter of the joints injected with IL-4 plus
IL-10 tended to be smaller than that of the vehicle injected joints
(2.630.16mm vs 2.910.29mm; p¼0.174). After a joint bleed, the
OARSI score as well as the Valentino score increased compared to the
unaffected joints. Intra-articular injection of IL-4 and IL-10 amelio-
rated cartilage degeneration caused by the joint bleed (mean change
in OARSI score in experimental joint compared to control joint for
vehicle injection 0.91.2 (p¼0.010) and for IL-4 plus IL-10 injection
0.51.8 (p¼0.216)). No effect on inﬂammationwas observed at 35 days
after the joint bleed for IL-4 plus IL-10 compared to vehicle (mean
Valentino score after IL-4 plus IL-10 injection 3.61.8 and for vehicle
injection 2.92.0 (p¼0.220)).
Conclusion: A single intra-articular injection of IL-4 plus IL-10 directly
after a single joint bleed limits cartilage degeneration, but not synovial
inﬂammation. Improved bioavailability of both cytokines might
improve the protective ability of both cytokines in development of
cartilage degeneration, and probably also inﬂammation.
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DIFFERENT CHANGES IN THE BIOMARKER CTX-II FOLLOWING
INTRA-ARTICULAR INJECTION OF HIGH MOLECULAR WEIGHT
HYALURONIC ACID AND ORAL NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS FOR PATIENTS WITH KNEE
OSTEOARTHRITIS: A MULTI-CENTER RANDOMIZED CONTROLLED
STUDY
M. Ishijima y, T. Nakamura z, K. Shimizu x, K. Hayashi k, H. Kikuchi {, S.
Soen #, G. Omori yy, T. Yamashita zz, Y. Uchio xx, J. Chiba kk, Y. Ideno k, H.
Kurosawa y, K. Kaneko y. the Research Group of Cartilage Metabolism;
y Juntendo Univ., Tokyo, Japan; zUniv. of Occupational and
Environmental Hlth., Fukuoka, Japan; xGifu Univ., Gifu, Japan; kGunma
Univ., Gunma, Japan; {Kinki Univ., Osaka, Japan; #Kinki Univ., Ikoma,
Japan; yyNiigata Univ., Niigata, Japan; zz Sapporo Med. Univ., Hokkaido,
Japan; xx Shimane Univ., Shimane, Japan; kk Tokyo Women's Med. Univ.,
Tokyo, Japan
Purpose: Intra-articular injections of hyaluronic acid (IA-HA) and oral
non-steroidal anti-inﬂammatory drugs (NSAIDs) are both recom-
mended by OARSI for the management of knee OA. However, their
molecular effects on the pathophysiology of knee OA remain unclear. A
C-terminal telopeptides of type II collagen (CTX-II) is biomarker
discovered as a marker of type II collagen degradation. Recently, CTX-II
has found to originate primarily from the interface between sub-
chondral bone and articular cartilage which is a site of potential
remodeling in OA. The regulation of CTX-II release is more reﬂective of
bone rather than cartilage metabolism. The aim of this study, the sub-
analysis of the multicenter RCT [the result of the primary endpoint
(OARSI 2012)] was to compare the changes of CTX-II in response to IA-
HA to those in response to NSAID treatment for knee OA.
Methods: A total of 200 patients with knee OA (K/L 1 to 3) were
registered from 20 hospitals and randomized to IA-HA (High molecular
weight 2,700 kDa HA) or NSAID (loxoprofen sodium). For patients
treated with NSAID, they used NSAID 3 tablets (180 mg)/day for 5
weeks. For patients treated with IA-HA, IA-HAwas conducted 5 times atoneweek intervals. The fasted second void urine samples collected from
all patients were stored at -80Co until analysis. uCTX-II levels were
corrected for urine creatinine concentration. The CTX-II data were
analyzed by the per protocol set (PPS).
Results: Half (100) of the patients were randomly allocated into the
NSAID group, and the other half allocated into the IA-HA group. After
the 5 week treatment period, 68 of 100 of the patients in the IA-HA
group and 58 of 100 of those in the NSAID group were eligible for CTX-II
analysis. At baseline, no signiﬁcant differences of baseline characteris-
tics were observed between IA-HA and NSAID groups. The Japanese
Knee Osteoarthritis Measure (JKOM) score of the patients in both the IA-
HA (-37.4%) and NSAID (-35.3%) groups were signiﬁcantly reduced
following treatment (p<0.001). The difference in the percent changes of
the JKOM score between the two intervention arms was -2.1% (90%CI;
-10.9 to 6.2%), demonstrating the non-inferiority of IA-HA to the NSAID
for the reduction in the clinical symptoms. uCTX-II levels were signiﬁ-
cantly reduced by the NSAID treatment. In contrast, uCTX-II levels were
signiﬁcantly increased by the IA-HA treatment. The percent changes of
uCTX-II by IA-HA treatment (11.6%) were signiﬁcantly different than
those of that by NSAID treatment (-9.0%) (p<0.0001). When the
patients were analyzed based on the radiographic severity of knee OA,
the differences of uCTX-II responses between the NSAID and IA-HA
were again observed.
Conclusions: We observed in this RCT that IA-HA treatment increased
uCTX-II levels, while oral NSAID reduced uCTX-II levels, while both
treatments improved symptoms of pts. with knee OA. The differences in
biomarker response suggest different modes of action, each with
a beneﬁcial effect on symptom: one being stimulatory of cartilage/bone
interface extracellular matrix type II collagen turnover (IA-HA) and the
other reducing such turnover.
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PHARMACOKINETICS OF A THERMALLY RESPONSIVE CURCUMIN
CONJUGATE FOR LOCAL ANTAGONISM OF NEUROINFLAMMATION
IN DISC HERNIATION
S.M. Sinclair y, J. Bhattacharyya y, D. Little z, R.D. Bowles y, D.M.
Gooden x, E.J. Toone x, A. Chilkoti y, L.A. Setton y,z. yDept. of BioMed.
Engineering, Duke Univ., Durham, NC, USA; zDept. of Orthopaedic
Surgery, Duke Univ., Durham, NC, USA; xDept. of Chemistry, Duke Univ.,
Durham, NC, USA
Purpose: Tumor necrosis factor alpha (TNFa) is believed to be a key
mediator of inﬂammatory events associated with herniated interver-
tebral disc (IVD). Local delivery of TNF antagonists via epidural injec-
tions to treat pain or dysfunction associated with herniated IVD has
been studied in the clinic with some success. We hypothesize that
sustained release of injectable depots containing cytokine antagonists
can be a safer, cost-effective treatment for relieving pain associated
with IVD herniation. We have designed novel drug conjugates
comprised of elastin-like polypeptides (ELP) and a small anti-inﬂam-
matory compound, curcumin, which has an excellent safety proﬁle in
clinical trials. ELPs are biocompatible, biodegradable polymers that are
soluble below a transition temperature (Tt,) and form micron-sized
depots above Tt. Here, we report on the pharmacokinetics and clearance
rates of injectable, ELP-curcumin conjugate ‘depots’ delivered to the
perineural space in mice.
Methods: A novel derivative of curcumin, monofunctional curcumin
carbamate (MCC, Fig 1), was chemically coupled to glutamate-con-
taining ELPs (Fig 2). Drug-carrier ratio, conjugate purity, Tt, and
hydrodynamic radius (Rh) were quantiﬁed with UV-Vis, RP-HPLC, and
dynamic light scattering. In vitro bioactivity of conjugates against TNFa-
induced proliferation was quantiﬁed with L929 cells as previously
described. For in vivo studies, the right sciatic nerve of C57BL/6 female
mice (n¼3 per group, 12 weeks old) was surgically exposed, and cur-
cumin or ELP-MCC (25ml, 150nmol) was delivered to the perineural
space. Blood was collected at times from 0.5 to 168 hours and tissues
were harvested at varying sacriﬁce times from 2 to 168 hours. Plasma
and solubilized tissue was analyzed for curcumin presence via
ﬂuorescence.
Results: ELP-MCC conjugates were synthesized and characterized to
have mean drug-carrier ratios of 5.7 to 1 (MW¼37.8kDa), >90% purity,
